| Literature DB >> 36013466 |
Nur Fadlin Saifulazmi1, Emelda Rosseleena Rohani2, Sarahani Harun2, Hamidun Bunawan2, Hamizah Shahirah Hamezah2, Nor Azlan Nor Muhammad2, Kamalrul Azlan Azizan2, Qamar Uddin Ahmed3, Sharida Fakurazi4,5, Ahmed Mediani2, Murni Nazira Sarian2.
Abstract
Exploration of the traditional medicinal plants is essential for drug discovery and development for various pharmacological targets. Various phytochemicals derived from medicinal plants were extensively studied for antiviral activity. This review aims to highlight the role of medicinal plants against viral infections that remains to be the leading cause of human death globally. Antiviral properties of phytoconstituents isolated from 45 plants were discussed for five different types of viral infections. The ability of the plants' active compounds with antiviral effects was highlighted as well as their mechanism of action, pharmacological studies, and toxicological data on a variety of cell lines. The experimental values, such as IC50, EC50, CC50, ED50, TD50, MIC100, and SI of the active compounds, were compiled and discussed to determine their potential. Among the plants mentioned, 11 plants showed the most promising medicinal plants against viral infections. Sambucus nigra and Clinacanthus nutans manifested antiviral activity against three different types of viral infections. Echinacea purpurea, Echinacea augustofolia, Echinacea pallida, Plantago major, Glycyrrhiza uralensis, Phyllanthus emblica, Camellia sinensis, and Cistus incanus exhibited antiviral activity against two different types of viral infections. Interestingly, Nicotiana benthamiana showed antiviral effects against mosquito-borne infections. The importance of phenolic acids, alkamides, alkylamides, glycyrrhizin, epicatechin gallate (ECG), epigallocatechin gallate (EGCG), epigallocatechin (EGC), protein-based plant-produced ZIKV Envelope (PzE), and anti-CHIKV monoclonal antibody was also reviewed. An exploratory approach to the published literature was conducted using a variety of books and online databases, including Scopus, Google Scholar, ScienceDirect, Web of Science, and PubMed Central, with the goal of obtaining, compiling, and reconstructing information on a variety of fundamental aspects, especially regarding medicinal plants. This evaluation gathered important information from all available library databases and Internet searches from 1992 to 2022.Entities:
Keywords: antiviral activities; bioactive compounds; medicinal plants; virus infections
Year: 2022 PMID: 36013466 PMCID: PMC9410304 DOI: 10.3390/life12081287
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Figure 1Virus infection route of transmission.
Mechanism of action of common antiviral drugs.
| Antiviral Drugs | Mechanism of Actions | Viruses |
|---|---|---|
| Acyclovir, | Valacyclovir and valganciclovir are hydrolyzed with the presence of esterases secreted from the intestine and liver into nucleoside analogs, acyclovir, and ganciclovir, respectively [ | HSV-1, HSV-2, and VZV |
| Ganciclovir, | Cytomegalovirus (CMV) and HSV-1, HSV-2 | |
| Amantadine, | Interrupts the ion-channel activity of the M2 protein of influenza A by deforming the subunits of the channel [ | Influenza A |
| Zidovudine (ZDV), | Both antiretroviral drugs work synergically through phosphorylation into zidovudine and lamivudine triphosphate, respectively, in host cells. Both triphosphate anabolites inhibit the enzyme for HIV reverse transcription and polymerization of hepatitis B virus, thus preventing the viral DNA elongation and viral multiplication [ | HIV and hepatitis B virus |
| Remdesivir | This nucleoside analog prodrug undergoes a tri-phosphorylation process into remdesivir triphosphate. The nucleoside triphosphate embodies the new strand as the substrate for SARS-CoV-2 RNA-dependent RNA polymerase [ | SARS-CoV-2 |
| Nirmatrelvir | Also known as PF-07321332, a modified version of PF-00835231, hydroxymethyl ketone derivative. Nirmatrelvir inhibits the 3CL protease activity, an active drug target of SARV-CoV-2 that stimulates the cleave of the viral protein polypeptide bond [ | SARS-CoV-2 |
Medicinal plants possessing antiviral activity causing common cold.
| Plant Name | Parts Used | Plant Extract | IC50/ED50/EC50/CC50/MIC100 | Assay | Cell Line Used | Mechanism of Action | Outcome |
|---|---|---|---|---|---|---|---|
| Root | 70% ethanol | MIC₁00 = 62 μg/mL) | Viral plaque | Vero, H-1 and BEAS-2B | Inhibition of rhinovirus replication | Plant showed anti-rhinovirus activity | |
| Ethyl acetate | MIC₁00 = 85 μg/mL | ||||||
| Hexane | MIC₁00 = 69 μg/mL | ||||||
| Aerial parts and root | IC50 = 3.2 μg/mL | MTT | Huh-7, Vero, and Vero E6 | Inhibition of HCoV-229E penetration into the cell and progeny shedding | HCoV-229E virucidal activity | ||
| Stem | Ethanol | IC50 = 1.17 ± 0.75 μg/mL | Virus yield reduction | LLC-MK2 | Inhibition of binding of HCoV-NL63 with Sai cell-surface receptor | HCoV-NL63 virucidal activity | |
| IC50 = 4.67 ± 1.21 μg/mL | Viral plaque | ||||||
| IC50 = 15.75 ± 6.65 μg/mL | Virus attachment | ||||||
| CC50 = 180.62 ± 63.04 μg/mL | MTT | ||||||
| Whole plant | Aqueous | CC50 = 938.43 μg/mL | Cell cytotoxicity, standard viral plaque, RSV-GFP virus replication inhibition | Human epithelial type 2: HEp2 with HeLa contaminant and A549 | Reduced RSV replication, RSV-induced cell death, RSV gene transcription, RSV protein synthesis, blocked syncytia formation | Antiviral therapy for respiratory syncytial virus (RSV) infection | |
| Whole plant | Aqueous | EC50 = 27.95 μg/mL | Cell cytotoxicity, standard viral plaque, RSV-GFP virus replication inhibition | Human epithelial type 2: HEp2with HeLa contaminant and A549 | Reduced RSV replication, RSV-induced cell death, RSV gene transcription, RSV protein synthesis, blocked syncytia formation | Antiviral therapy for respiratory syncytial virus (RSV) infection |
Figure 2The mechanism of actions of antiviral agents from P. asiatica and C. trichotomum against the RSV. Once the virus penetrates the host cell, the life cycle of the RSV begins that can be targeted for antiviral compounds extracted from the whole plant of P. asiatica and C. trichotomum. The plant extract reduced RSV replication, RSV-induced cell death, RSV gene transcription, RSV protein synthesis, and blocked syncytia formation.
Figure 3Overview of medicinal plants for treating common cold infections.
Medicinal plants possessing antiviral activity against influenza.
| Plant Name | Parts Used | Plant Extract | IC50/ED50/EC50/CC50 | Assay | Cell Line | Mechanism of Action | Outcome |
|---|---|---|---|---|---|---|---|
|
| Peel [ | 80% ethanol | IC50 = 6.45 μg/mL | Cytotoxicity, Cytopathic effect reduction | MDCK cells | Inhibition of influenza virus replication | Plant has high inhibitory effect on Influenza A virus replication in vitro |
| Fruit [ | Polyphenol extract | Real-time PCR, viral plaque, TCID50, MTT | Changed viral surface glycoproteins and promoted damage to virion integrity | Plant exhibit virucidal effect on Influenza A virus | |||
| AerialRoots | Polyphenol-rich methanol and ethanol extract | EC50 = 3.6 μg/mL | Cytopathogenic effect reduction | MDCK cells | Inhibited the CPE of Influenza A/Rostock virus in CEF cells | Plant extract showed virucidal effect on Influenza A/Rostock virus | |
| IC50 = 72 μg/mL | CEF cells | ||||||
| Roots | Aqueous fraction | MIC100 = 2.2–2.5 μg/mL | Cytopathogenic effect reduction, viral plaque | Vero, H-1, and BEAS-2B cell line | Eliminated viral cytopathic effect | Plant root contains a potent water-soluble antiviral ingredient | |
| Roots | Ethanol 55% extract | MIC100 = 33.5 μg/mL | Cytopathogenic effect reduction, viral plaque | Vero, H-1, and BEAS-2B cell line | Eliminated viral cytopathic effect | Plant root contains a potent water-soluble antiviral ingredient | |
| Ethyl acetate extract | MIC₁00 = 348 μg/mL | ||||||
| Dinstinct variety of | CYSTUS052 extract | Effective dose = 50 μg/mL | Aerosol formulation treatment, plaque reduction, hemagglutination | MDCK cells | Prevented adsorption of the Influenza A virus to host cells | Plant extract reduced 90% Influenza A viral plaque formation | |
| Inbred female Balb/c and C57Bl/6 mice (age of 6–8 weeks) | Protected the animals against clinical disease symptoms caused by Influenza A virus infection | CYSTUS052-treated mice did not develop disease | |||||
| Root and rhizomes | Glycyrrhizin | IC50 = 0.0081 μg/mL | Cell viability, | Natural killer (NK) cells, Human peripheral blood mononuclear cells (PBMC) | Reduced H5N1-induced cytokine expression, H5N1-induced caspase activation, and H5N1-induced apoptosis | Glycyrrhizin may develop into potential anti-influenza drug | |
| Fruit | Polyphenol-rich extract, CSD 3 | IC50 = 0.3 μg/mL | Plaque, hemagglutination, hemolysis | MDCK cells | Reduced cell-viral binding, hemagglutination, and hemolytic activities and infectivity of Influenza A/Udorn/72(H3N2) | Reduced primary transcription of Influenza A/Udorn/72(H3N2) virus-infected MDCK cells. | |
| Fruit | Fruit juice at pH 4.4 ± 0.1 | IC50 = 6000 ± 800 μg/mL | Cytotoxicity, plaque reduction | MDCK cells | Suppressed viral entry, restrained viral transmission from cell to cell, and modulated the release of cytokines | Plant’s fruit exhibited multiple modes of therapeutic action against influenza infection | |
| CC50 = 810 ± 30 μg/mL | A549 cells | ||||||
|
| Branches and leaves [ | 1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG) dissolved in DMSO | CC50 = 29.59 ± 4.32 μg/mL | Water-soluble tetrazolium-1, Plaque-forming unit (PFU) | MDCK cells, A549 cells | Inhibited hemagglutination of chicken red blood cells induced by Influenza A virus, reduced virus budding and progeny virus release from infected cells | PGG as a promising antiviral agent against influenza A virus |
| Roots [ | Fraction containing phyllaemblicin B | CC50 = 6.9 ± 0.9 μg/mL | Cytopathic end-point, Cytotoxicity | MDCK cells, Vero cells | Exerted inhibitory effect on Influenza A H3N2 strain | Both plant fractions showed potential anti-viral activities against Influenza A H3N2 strain | |
| Fraction containing glochicoccinoside D | CC50 =13.4 ± 2.1 μg/mL | ||||||
| Leaves | Cathecin extract of (−)-epigallocatechin gallate (EGCG) | EC50 = 22–28 μg/mL | Plaque inhibition, Virus growth inhibition, Hemagglutination inhibition, Neuraminidase inhibition, MTT | MDCK cells | Inhibited hemagglutination inhibition activity, suppressed viral RNA synthesis, inhibited neuraminidase activity, inhibited viral attachment, altered viral and cell membrane | Inhibitory potential on Influenza A virus was shown in order of ECGC > ECG > EGC | |
| Cathecin extract of (−)-epicatechin gallate (ECG) | EC50 = 22–40 μg/mL | ||||||
| Cathecin extract of (−)-epigallocatechin (EGC)) | EC50 = 309–318 μg/mL |
Figure 4An overview of influenza mechanism of action via inhibition of viral replication and treatment using selected antiviral medicinal plants.
Medicinal plants possessing antiviral activity causing sexually transmitted disease.
| Plant Name | Parts Used | Plant Extract | IC50/ED50/EC50/CC50 | Assay | Cell Line | Mechanism of Action | Outcome |
|---|---|---|---|---|---|---|---|
| Leaves | n-hexane | IC50 = 32.05 µg/mL, 72.62 μg/mL | Plaque reduction, MTT | Vero | Inhibited HSV-1 and HSV-2 viral plaque formation | n-hexane and dichloromethane extracts exhibited better antiviral activity against HSV-1 than methanol extract | |
| Dichloro-methane | IC50 = 44.50 ± 2.66 µg/mL, 65.19 µg/mL | ||||||
| Methanol | IC50 = 64.93 µg/mL, 65.13 μg/mL | ||||||
| Leaves | n-hexane | IC50 = 60.00 µg/mL, 46.52 µg/mL | Plaque reduction, MTT | Vero | Inhibited HSV-1 and HSV-2 viral plaque formation | Methanolic extract possessed the greatest anti-HSV-1. | |
| Dichloromethane | IC50 = 55.69 ± 4.41 µg/mL, 49.63 µg/mL | ||||||
| Methanol | IC50 = 37.39 µg/mL, 72.64 µg/mL | ||||||
| Dinstinct variety of | Aqueous (boiled) | EC50 = 8.06 μg/mL CC50 = 250 μg/mL | Time-of-addition (TOA), | HEK293T, H9, and LC5 | Blocked primary virus attachment to cells by selective targeting of the viral envelope glycoproteins | Exhibited broad antiviral activity with low risk of virus resistance | |
| Polyphenol- | CC50 = 1200 μg/mL | Plant fraction possessed antiviral activity on HIV-1LAI | |||||
| Whole plant | Pure compound (caffeic acid) | EC50 = 15.3 µg/mL, 87.3 µg/mL | XTT | BCC-1/KMC | Inhibited HSV virus replication | Caffeic acid possessed the best anti-HSV viral activity than chlorogenic acid | |
| Pure compound (chlorogenic acid) | EC50 = 47.6 µg/mL, 86.5 µg/mL | ||||||
| Leaves, stem | Methanol | LC50 leaves = 875 µg/mL | Virus attachment | Vero | Inhibited HSV-1 attachment | 0.1 LC50 gave higher cell survival |
Figure 5The mechanism of action of antiviral agent from C. incanus against HIV via inhibition of viral attachment. The mechanism of C. nutans and C. siamenensis plant extractions against HSV-1 and HSV-2 virus via inhibition viral plaque formation, whereas the mechanism of P. minus and P. major is via inhibition of viral attachment.
Medicinal plants possessing antiviral activity causing by dermatology-related disease.
| Plant Name | Parts Used | Plant Extract | IC50/ED50/EC50/CC50 | Assay | Cell Line | Mechanism of Action | Outcome |
|---|---|---|---|---|---|---|---|
| Whole plant | Juice | CC50 = 70–75 µg/mL | VACV plaque | RK-13 | Prevented replication of monkeypox virus and variola virus | ||
| Leaves | 5% | IC50 = 76 µg/mL | Double-blinded clinical trial | 125 patients infected with VCV | Lowered the chance of developing clinical disease | Exhibited a positive curing effect against VZV infection | |
| Whole plant | Essential oil | Not identified | Plaque reduction | RC-37 | Interacted with the viral envelope and glycoproteins | Reduced the infectivity of the HSV-2 virus | |
| Leaves | Hot glycerin extract | CC50 = 3238 µg/mL | Cytotoxicity, plaque reduction | Vero | Inhibited HSV replication pre-attachment of virus on the cell | Showed significant inhibitory effect on HSV | |
| IC50 = 536 µg/mL | Inhibited HSV replication post attachment of virus replication | ||||||
| Leaves | Ethanol | EC50 = 9 μg/mL | Plaque reduction, cytotoxicity | Vero | Inhibited the lysis plaque, inhibited virus absorption | Exhibited as the potent virus absorption inhibitors | |
| Whole plant | Ethanol | IC50 = 26.09 µg/mL | Plaque reduction, cell viability | MRC-5 | Inhibited the replication of varicella-zoster virus | Showed potent inhibitory effects on VZV gene expression and replication | |
| Whole plant | Aqueous | IC50 = 70.3 μg/mL | Cytotoxicity, MTT, immunoblotting | Vero | Blocked viral infection proinflammatory response | Showed antiviral and anti-inflammatory activities | |
| Leaves | Polyphenon E (poly E) | Concentration 1 and 5 µg/mL | Immunofluorescence | TCL-1 | Inhibited growth of HPV-immortalized cervical epithelial (TCL-1) cells | All compounds showed inhibitory response on growth of HPV and poly E | |
| Epigallocatechin gallate (EGCG) | |||||||
| Leaves (red and green leaves) | Ethanol | Concentration of 10 and 15 mg/mL | Cytotoxicity | Hep-2 | Inhibited measles virus replication | Showed antiviral activities on pre and post-inoculative treatment | |
| Root and stolon | Aqueous | IC50 = 0.056 μg/mL | XTT | Human foreskin | Suppressed EV71 replication | Showed antiviral activity against EV71 and CVA16 infection | |
| Glycyrrhizic acid | 200 μg/mL | MTT, plaque forming | Vero | Blocked viral replication of EV71 and CVA16 | Inhibited EV71 and CVA16 replication | ||
| Roots | Fraction containing glochicoccinoside D | IC50 = 2.6 ± 0.7 μg/mL | Cytopathic end-point, Cytotoxicity | MDCK, Vero | Inhibited EV71 | Showed potential anti-viral activities against EV71 | |
| Fraction containing phyllaemblicin C | IC50 = 2.6 ± 0.8 μg/mL |
Figure 6Mechanisms and compounds of medicinal plants that have antiviral activities against dermatology-related viruses.
Medicinal plants possessing antiviral activity causing mosquito-borne viral disease.
| Plant Name | Part Used | Plant Extract | IC50/ED50/EC50/CC50 | Assay | Cell Line Used | Mechanism of Action | Outcome |
|---|---|---|---|---|---|---|---|
| Leaves | Coumarin based | TD50 = 535.91 | MTT | C6/36 | Inhibited C6/36 cell lines and dengue virus | Petroleum ether extract had the strongest inhibitory effect on dengue virus | |
| Petroleum ether | ED50 = 47.43 | ||||||
| Whole plant | Fucoidan | Concentration of 10 μg/mL | Focus-forming | BHK-21 | Inhibited virus infection | Fucoidan reduced DENV-2 infectivity by 20% at 10 μg/mL | |
|
| Aerial part | 80% ethanol | IC50 31.04 μg/mL | Anti-inflammatory, anti-dengue, immune-modulating activity | Naïve Huh-7 | Anti-inflammatory, anti-dengue virus and immune-modulating activity | Possessed moderate anti-dengue virus activity |
| Leaves [ | Chloroform | CC50 of 25 μg/mL | MTT, immunofluorescence | C6/36, A549 | Inhibited dengue viral 2 in pre-entry replication step and | Showed virucidal activity against dengue virus 2 | |
| Leaves and flowers | Methanolic | 400 µg/mL | Viral plaque, indirect immunofluorescence | BHK-21 and Vero | Protected cell monolayers pre-treated cells before dengue virus-2 infection | Exhibited anti-DENV-2 activity on pre-incubated cells before dengue virus-2 infection | |
|
| Leaves [ | Chloroform | CC50 = 1000 μg/mL | Plaque forming, cytotoxicity, anti-DENV2 | LLC-MK2 | Inhibited DENV2 growth | Possessed promising anti-dengue properties |
| Aqueous | CC50 = 10437 μg/mL | MTT, foci forming unit reduction (FFURA) | Vero | Inhibited the virus replication, decreased number of dengue viral foci | |||
|
| Whole plant [ | Aqueous | Min concentration to inhibit the plaque = 10 μg/mL | Viral plaque, helicase, protease | The monkey kidney cells, Vero | Inhibited viral attachment, inhibited helicase and protease activities | Showed virucidal activity on Chikungunya virus |
|
| |||||||
|
| |||||||
| Leaves | Chloroform | EC50 = 29.9 ± 0.9 μg/mL | Cytopathic effect inhibition and cytotoxicity | African monkey kidney epithelial (Vero) | Showed cytopathic effect, inhibitory activity on Vero cells and reduction in the Chikungunya viral load | Showed virucidal activity on Chikungunya virus | |
| Leaves | Ethyl acetate | EC50 = 32.4 ± 1.3 μg/mL | African monkey kidney epithelial (Vero) | ||||
| Leaves | CHKVmab extract | EC50 = 390.8 μg/mL | Plaque reduction | Vero (ATCC, CCL-81) | Neutralization activity against CHIKV | Plant monoclonal antibodies have the potential to be used as effective treatment to prevent CHIKV infection | |
| EC50 = 130.5 μg/mL | |||||||
| Aerial parts | Aqueous | CC50 = 3000 µg/mL IC50 = 100 µg/mL | Plaque-forming, Immunofluorescence | Vero and human-derived Huh7.5 hepatoma | Prevented the viral entry into host cells | Promising sources of naturally derived antiviral compounds to prevent ZIKV | |
| Fresh aerial parts | Aqueous | CC50 = 1044 ± 106.2 μg/mL | MTT, genotoxicity, viral inactivation, Time-of-drug-addiction | Vero | Inhibited early steps of the viral replication | Showed antiviral activity against historical | |
| CC50 = 657 ± 15.7 μg/mL | A549 | ||||||
| CC50 = 353 ± 84.4 μg/mL | Human primary keratinocytes | ||||||
| CC50 = 820 ± 26.5 μg/mL | Fibroblast (FMa) | ||||||
| IC50 = 19.5 ± 4.8 μg/mL |
Figure 7Overview of medicinal plants for treating mosquito-borne virus. C. nutans, S. nigra, C. papaya inhibited the replication of DENV-2 virus. O. tenuiflorum, P. kurroa, and T. chebula inhibited the viral attachment. R. excelsa and V. amygdalina inhibited the viral load of Chikungunya virus. N. benthamiana inhibited the early replication, whereas A. theiformis inhibited the entry of Zika virus.
Medicinal plants, their active compounds, and mechanism of action on antiviral activity.
| Plant | Active Compound (s) | Mechanism of Action |
|---|---|---|
|
| Catechins and A-type pro-anthocyanidins, cyanidin-3- | Bind to surface of influenza virus and prevent the influenza virus from entering and replicating in the host cell [ |
| Plant lectins bind to host cell membranes and prevent the influenza virus hemagglutinin’s attachment to host cells [ | ||
| Block the ability of HIV virions to infect host cells [ | ||
|
| Clinamides and 2- | Promote down-regulation of IFN-γ and exhibit immune-modulating activities [ |
| monogalactosyl diglyceride (MGDG) and digalactosyl diglyceride (DGDG). | Anti-HSV activities at post-infection stage [ | |
| 132-hydroxy-(132- | Affected the viral adsorption and penetration of HSV into host cells [ | |
| Phaeophorbide A | Inhibit the making of dengue virus RNA and protein in infected cells [ | |
| Caffeic acid derivatives and cichoric acid | Enhanced innate immunity through activation of the neutrophils, macrophages, polymorphonuclear leukocytes (PMN), and natural killer (NK) cells [ | |
| Caffeic acid derivatives, alkylamides, polysaccharides | Suppress cytokine and chemokine production from human blood monocytes stimulated by influenza viruses [ | |
|
| Caffeic acid, chlorogenic acid | Inhibit replication of HSV-1, HSV-2, ADV-3 and ADV-11 [ |
|
| Glycyrrhizin | Inhibition of influenza virus replication by inhibiting virus polymerase activity [ |
| Glycyrrhizic acid | Targeting early infection of coxsackievirus A16 on Vero cells to deactivate or inhibit coxsackievirus A16 infection [ | |
|
| Phyllaemblicin B, phyllaemblicin C, and glochicoccinoside D | Displayed anti-viral activities and inhibitory activities against influenza A virus (H3N2), Enterovirus (EV71), coxsackievirus B3 and HSV-1[ |
|
| Epigallocatechin gallate (EGCG) | Inhibits hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus [ |
| Epicatechin gallate (ECG) and EGCG | Inhibits neuraminidase activity and blocks the function of viral neuraminidases of the influenza virus [ | |
| Exhibits hemagglutination inhibition activity [ | ||
| Suppresses viral RNA synthesis in MDCK cells [ | ||
| Epigallocatechin (EGC) | Inhibits neuraminidase activity and blocks the function of viral neuraminidases of the influenza virus [ | |
|
| flavan-3-ols and proanthocyanidins | Bind to the virus surface and inhibit the binding process of hemagglutinin to cellular receptors [ |
| Prevent primary attachment of the HIV-1 and HIV-2 onto the cell surface [ | ||
| Blocking the viral attachment to cells and selective targeting the viral envelope glycoprotein [ | ||
|
| capsidiol 3-acetate | Inducing self-defense mechanism in |
Figure 8Overview of antiviral medicinal plants and their active compounds. The active compounds that were isolated were derived either from fruits, leaves, flowers, roots, or stems of plants.